Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Share:
Related REGN
Q2 Earnings Report Card: Biotech
Benzinga's Top Downgrades
FDA accepts dupilumab BLA for review; action date March 29, 2017 (Seeking Alpha)
Related AGN
Will Allergan Buy Gilead? Don't Count On 'The Mother Of All Blockbusters'
Jim Cramer: The Pharmaceutical 'Good Guys' Need To Stand Up
Unexpected Twist: Pfizer Scraps Breakup Following Dead Allergen Merger (Investor's Business Daily)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Aug 2016BairdDowngradesOutperformNeutral
Jun 2016BernsteinInitiates Coverage onOutperform
Apr 2016Wells FargoDowngradesOutperformMarket Perform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

View Comments and Join the Discussion!